Navigation Links
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Date:4/15/2008

M Santegoets, Ph.D., from the Department of Medical Oncology

and Pathology of Vrije Universiteit Medical Center located in

Amsterdam, Netherlands. The data suggested an ipilimumab dose-related

association with increased T-cell activation, as well as associated

anti-tumor activity from the initial 12 patients that was previously

reported at the June 2007 American Society of Clinical Oncology (ASCO)

meeting.

In the Phase 1 clinical trial, 28 patients with metastatic HRPC have

been enrolled, including 12 patients in the dose-escalation cohort

(0.3, 1, 3 or 5 mg/kg ipilimumab) and 16 patients in the expansion

cohort (3 mg/kg ipilimumab). The dose of GVAX immunotherapy for

prostate cancer used in this combination trial is comparable to that

currently being evaluated in Cell Genesys' ongoing Phase 3 program. The

treatment combination was generally well-tolerated. Adverse events

associated with this regimen are consistent with data previously

reported from this study.

-- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent

induction of CD8+ T cell activation and clinical responses" (Abstract

#2539)

Preliminary data from an ongoing Phase 1 study of escalating doses of

ipilimumab in combination with GM-CSF (sargramostim) were presented by

Lawrence Fong, Ph.D., from the University of California, San Francisco,

San Francisco. Of the six patients treated at 3 mg/kg ipilimumab, three

experienced confirmed decreases in prostate-specific antigen (PSA)

serum levels of over 50%, and one of these patients experienced a

partial response in hepatic metastases.

In the Phase 1 clinical trial, 26 patients with HRPC received treatment

with a 28-day cycle of daily doses of 250 mg/m2 of GM-CSF for 14 days

in combination with
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... on study results demonstrating survival advantage ... months when added to standard therapy, -- First study ... BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: PHRM ) ... positive opinion to recommend approval of Thalidomide,Pharmion(R) for use in ...
... with Fractionated Lasers Or in ... the Eyes, WALTHAM, Mass., Jan. 24 When it ... no longer the only option. According to the,American Academy of ... who is interested in non-surgical options to obtain the,best results. ...
Cached Medicine Technology:Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 2Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 3Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 4
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... news release is available in French . ... factors in 14 year old teens, including brain structure and ... 70% accuracy who will go on to develop binge drinking ... of conscientiousness, and other variables such as life events and ... of binge drinking. Whether or not the child had ...
(Date:7/9/2014)... is for more than watching World Cup highlights, Brian ... skateboarders landing in unfortunate positions on railings. A University ... Dermatology Online Journal shows that YouTube also allows ... the public on topics of skin cancer and prevention. ... is the future of how we communicate around the ...
(Date:7/9/2014)... 9, 2014) A retrospective study conducted by researchers ... reports that among adults with intellectual and developmental disabilities, ... of years receiving dental care increased. The findings, published ... Dentistry , may help improve interventions designed to address ... , The researchers reviewed the dental records of 107 ...
(Date:7/9/2014)... 9, 2014 A study published in the scientific ... and Robert Bonin, two researchers at Universit Laval, reveals ... a new method that involves rekindling pain so that ... to novel means to alleviate chronic pain. , The ... and Institut universitaire en sant mentale de Qubec (IUSMQ) ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2
... productivity industry, WASHINGTON, March 31 The ... on Health (NBCH), two,nationally-recognized non-profit organizations focused on ... and quality of life, are,partnering to host the ... will take place February 9-11, 2009 at the ...
... of elderly patients could cut their total mortality by ... a third, according to a new study presented today ... in Chicago and published simultaneously in the New England ... the Very Elderly Trial (HYVET), which is coordinated by ...
... Chicago, IL, March 31, 2008 New data ... technology found that in patients living with type ... burden in the coronary arteries compared to glimepiride, ... data stem from the PERISCOPE (Pioglitazone Effect on ...
... DIEGO, March 31 Amira Pharmaceuticals, a small,molecule ... of,compounds to treat inflammatory disease, today announced the ... directors: Dennis M. Fenton, Ph.D.,and Stephen W. Kaldor, ... pharmaceutical and biotechnology experience,including over two decades at ...
... Focus on Delivering on ... 2008 Free Cash Flow Target, SIOUX ... the leading provider of media and,connectivity solutions to hospitality and healthcare ... Conference at The Palms,Hotel in Las Vegas on Wednesday, April 2. ...
... 31 Greenway Medical Technologies,announced today its expanded ... Quality Reporting Initiative (PQRI) and Pay for,Performance (P4P) ... technology (HIT) adoption., The PQRI, which was ... Medicare, Medicaid, and SCHIP Extension Act of 2007, ...
Cached Medicine News:Health News:Integrated Benefits Institute and National Business Coalition on Health to Host First Annual Health and Productivity Forum 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors 2Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 2Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 3Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 4Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 5Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 2Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 3Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 4
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
... Ruschelit® PVC. Murphy eye-oral. High volume/low ... Oral Cuffed Single use. For improved ... of the tube by incorporating a ... cuff. Thermosensitive Ruschelit® PVC adapts to ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Medicine Products: